Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 91 clinical trials
T-DM1 and Palbociclib for Metastatic HER2 Breast Cancer

This is a randomized phase II study to evaluate if the combination of T-DM1 with palbociclib improves progression-free survival compared to single agent T-DM1in patients with metastatic HER2

breast cancer
metastasis
her2/neu-positive breast cancer
HER2
palbociclib
  • 45 views
  • 26 Jan, 2021
  • 16 locations
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma

The proposed study is a single-arm, multi-center, open-label phase II study of the combination of palbociclib and ibrutinib in patients with previously treated mantle cell lymphoma to evaluate

immunosuppressive agents
hepatitis b surface antigen
immunohistochemistry
measurable disease
prednisone
  • 23 views
  • 25 Jan, 2021
  • 8 locations
The Resistance and Immune Response to Palbociclib in Breast Cancer

Breast Cancer (BC) treated with Palbociclib in combination with endocrine therapies.

breast cancer
endocrine therapy
hormone therapy
palbociclib
  • 4 views
  • 22 Jan, 2021
  • 1 location
Los Tres Paso: Neoadjuvant Palbociclib Monotherapy Concurrent Chemoradiation Therapy Adjuvant Palbociclib Monotherapy in Patients With p16INK4a Negative HPV-Unrelated Head and Neck Squamous Cell Carcinoma

The purpose of this study is to evaluate the results of treating patients with HPV-unrelated head and neck squamous cell carcinoma with neoadjuvant single-agent palbociclib, followed by

caries
x-rays
ct scan
chemoradiotherapy
intensity-modulated radiation therapy
  • 6 views
  • 28 Jan, 2021
  • 1 location
Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy

PROMETEO II is a single-arm window of opportunity trial to evaluate biologic and anti-proliferative effects of palbociclib and letrozole in HR+/HER2-negative operable breast cancer (BC) patients

cancer treatment
docetaxel
doxorubicin
HER2
tumor cells
  • 2 views
  • 25 Jan, 2021
  • 5 locations
Determinants of Resistance to First-line Therapy With an AI and Palbociclib for HR+ MBC

The goal of this research study is to determine if the investigators can predict which participants will respond to an aromatase inhibitor and palbociclib for metastatic breast cancer and which

gonadotropin releasing hormone
locally advanced breast cancer
progesterone
stage iv breast cancer
measurable disease
  • 12 views
  • 24 Jan, 2021
  • 1 location
Locoregional Treatment and Palbociclib in de Novo Treatment Naive Stage IV ER+ HER2- Breast Cancer Patients

Approximately 3.5% to 6% of newly diagnosed breast cancer patients are stage IV metastatic. De novo metastatic breast cancer accounts for 20% to 25% of these cases. Despite a decrease in mortality in Europe and North America due to early detection and access to treatment, breast cancer remains the 2 …

her2-negative breast cancer
primary tumor
luminal
adenocarcinoma
HER2
  • 0 views
  • 25 Jan, 2021
  • 34 locations
A Study of the Use of Text Message Reminders to Take Palbociclib

The purpose of this study is to find out whether it is feasible (acceptable to participants) to use a smartphone app to send text message reminders to take palbociclib, and whether these

palbociclib
fulvestrant
breast carcinoma
  • 8 views
  • 27 Jan, 2021
  • 7 locations
HOPE: Olaparib Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated HR+ HER2-metastatic Breast Cancer

The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive breast

  • 0 views
  • 04 Mar, 2021
  • 1 location
PalbocIclib in PreMenopausal Women With ER Positive/HER-2 Negative MetAstatic Breast Cancer

. Patients will be randomized to receive either palbociclib + exemestane + OFS (Arm 1) or exemestane +OFS (Arm 2). Treatment will be continued until disease progression, unacceptable toxicities, or

  • 0 views
  • 23 Jan, 2021
  • 1 location